“Pre-Covid most of the pharma stocks rallied and the same was the case with Biocon and then it has done nothing in the last two years. So if I have to look at in terms of market cap, the stocks look cheap but in terms of valuation, it looks fully valued at current levels as well. I do not see any major upside happening in Biocon.”
Michael Burry calls Nvidia ‘heck of a trade’ after Huang’s scandal sparks $430 bn selloff. Why is Big Short fame dismissing fears?
Michael Burry sees a near-term trading opportunity in Nvidia despite his broader concerns about AI valuations. The Big Short investor believes Jensen Huang’s personal controversy
November 11, 2026